IGFBP‐4 enhances VEGF‐induced angiogenesis in a mouse model of myocardial infarction
Open Access
- 28 June 2020
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (16) , 9466-9471
Abstract
Vascular endothelial growth factor (VEGF) is a well‐known angiogenic factor, however its ability in promoting therapeutic angiogenesis following myocardial infarction (MI) is limited. Here, we aimed to investigate whether dual treatment with insulin‐like growth factor binding protein‐4 (IGFBP‐4), an agent that protects against early oxidative damage, can be effective in enhancing the therapeutic effect of VEGF following MI. Combined treatment with IGFBP‐4 enhanced VEGF‐induced angiogenesis and prevented cell damage via enhancing the expression of a key angiogenic factor angiopoietin‐1. Dual treatment with the two agents synergistically decreased cardiac fibrosis markers collagen‐I and collagen‐III following MI. Importantly, while the protective action of IGFBP‐4 occurs at an early stage of ischemic injury, the action of VEGF occurs at a later stage, at the onset angiogenesis. Our findings demonstrate that VEGF treatment alone is often not enough to protect against oxidative stress and promote post‐ischemic angiogenesis, whereas the combined treatment with IGFBP4 and VEGF can utilize the dual roles of these agents to effectively protect against ischemic and oxidative injury, and promote angiogenesis. These findings provide important insights into the roles of these agents in the clinical setting, and suggest new strategies in the treatment of ischemic heart disease.Keywords
Funding Information
- China Postdoctoral Science Foundation (2018M642045)
- National Natural Science Foundation of China (81903989, 81672849, 81600313)
This publication has 13 references indexed in Scilit:
- Opposing Roles of Wnt Inhibitors IGFBP-4 and Dkk1 in Cardiac Ischemia by Differential Targeting of LRP5/6 and β-cateninCirculation, 2016
- VEGF165Amicrosphere therapy for myocardial infarction suppresses acute cytokine release and increases microvascular density but does not improve cardiac functionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2015
- BRCA1 is an essential regulator of heart function and survival following myocardial infarctionNature Communications, 2011
- Intramyocardial Injection of Vascular Endothelial Growth Factor Gene Improves Cardiac Performance and Inhibits Cardiomyocyte ApoptosisEuropean Journal of Heart Failure, 2007
- Administration of Vascular Endothelial Growth Factor Adjunctive to Fetal Cardiomyocyte Transplantation and Improvement of Cardiac Function in the Rat ModelJournal of Cardiovascular Pharmacology and Therapeutics, 2005
- 8-Oxo-dGTPase, Which Prevents Oxidative Stress-Induced DNA Damage, Increases in the Mitochondria From Failing HeartsCirculation, 2001
- Evidence for DNA damage in patients with coronary artery diseaseMutation Research - Genetic Toxicology and Environmental Mutagenesis, 2001
- Efficacy of intracoronary or intravenous VEGF165in a pig model of chronic myocardial ischemiaJACC, 2001
- Vascular-specific growth factors and blood vessel formationNature, 2000
- Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat—angiogenesis and angioma formationJACC, 2000